Does Wegovy Cause Dizziness?
Yes, dizziness is a reported side effect of Wegovy (semaglutide), occurring in clinical trials and post-marketing data. In the STEP trials, about 8% of patients on the 2.4 mg dose experienced dizziness, compared to 4% on placebo.[1] The prescribing information lists it under common adverse reactions, often linked to gastrointestinal effects like nausea or low blood sugar.[2]
How Common Is Dizziness on Wegovy?
Dizziness affects 5-12% of users across doses, per Novo Nordisk's label. It's more frequent during dose escalation (weeks 5-16) and typically mild to moderate, resolving without stopping treatment.[1][2] Women and those with lower BMI report it slightly more often.
Why Does Wegovy Cause Dizziness?
Semaglutide slows gastric emptying and suppresses appetite, which can lead to dehydration, low blood pressure, or hypoglycemia—triggers for dizziness. Rapid weight loss (up to 15% body weight) may also contribute via electrolyte shifts or orthostatic hypotension.[2][3]
What Should You Do If You Feel Dizzy on Wegovy?
Stay hydrated, eat small frequent meals, and rise slowly from sitting or lying. If severe or persistent, contact your doctor; they may pause dose increases or check blood sugar/blood pressure. Avoid driving until it passes.[2]
How Does Wegovy's Dizziness Compare to Ozempic or Mounjaro?
Wegovy's rate (8%) matches Ozempic's (semaglutide 1-2.4 mg), but Mounjaro (tirzepatide) reports lower at 5-7%, possibly due to different GLP-1/GIP action. All carry similar warnings.[1][4]
When Does Dizziness Usually Start and Stop?
Most cases begin in the first 4-8 weeks during titration, peaking around week 12, then fade as the body adjusts. Only 1-2% discontinue due to it.[1][2]
Are There Serious Risks Tied to Dizziness?
Rarely, it signals pancreatitis, gallbladder issues, or severe GI reactions—monitor for vomiting or abdominal pain. No direct link to falls or strokes in trials, but caution advised for elderly or those with heart conditions.[2][3]
[1]: Novo Nordisk. Wegovy Prescribing Information. https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/safety-profile-adverse-events.html
[2]: FDA. Wegovy Label. https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/215256s007lbl.pdf
[3]: NEJM. STEP 1 Trial (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[4]: FDA. Mounjaro Label. https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/215866s000lbl.pdf